Royalty Pharma plc (RPRX) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Royalty Pharma financial statements at a glance

Royalty Pharma reported revenue of $2.38 billion for fiscal year 2025 (ended December 31, 2025), up 5.1% from fiscal year 2024. Net income was $770.95 million, a net margin of 32.4%.

At the end of fiscal year 2025 it had total assets of $19.62 billion, total liabilities of $9.91 billion and shareholders' equity of $6.48 billion, with cash and short-term investments of $1.49 billion and total debt of $8.95 billion.

Its operations brought in $2.49 billion of cash, leaving free cash flow of $2.49 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

RPRX logo

Royalty Pharma plc

RPRXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
2.38B
Prev Year: 2.26B
YoY: +5.1%
Operating Revenue
2.38B
Prev Year: 2.26B
YoY: +5.1%
Equity in Earnings of Affiliates
29.09M
Prev Year: 29.61M
YoY: -1.8%
Gain on Sale of Securities
24.01M
Prev Year: 188.46M
YoY: -87.3%
Other Operating Expenses
-295.84M
Prev Year: 732.46M
YoY: -140.4%
Provision for Doubtful Accounts
89.03M
Operating Expense
818.67M
Prev Year: 971.13M
YoY: -15.7%
Selling General and Administrative
573.48M
Prev Year: 236.67M
YoY: +142.3%
General and Administrative Expense
573.48M
Prev Year: 236.67M
YoY: +142.3%
Other General and Administrative
573.48M
Prev Year: 236.67M
YoY: +142.3%
Research and Development
452.00M
Prev Year: 2.00M
YoY: +22500.0%
Operating Income
1.56B
Prev Year: 1.29B
YoY: +20.7%
Net Non Operating Interest Income Expense
-274.07M
Prev Year: -178.17M
YoY: -53.8%
Non-operating Interest Income
33.59M
Prev Year: 47.34M
YoY: -29.0%
Non-operating Interest Expense
307.66M
Prev Year: 225.51M
YoY: +36.4%
Other Income Expense
38.75M
Prev Year: 216.54M
YoY: -82.1%
Other Non-operating Income (expense)
-14.35M
Prev Year: -1.53M
YoY: -839.1%
Pre-tax Income
1.32B
Prev Year: 1.33B
YoY: -0.5%
Net Income Common Stockholders
770.95M
Prev Year: 858.98M
YoY: -10.2%
Net Income
770.95M
Prev Year: 858.98M
YoY: -10.2%
Net Income Including Non-Controlling Interests
1.32B
Prev Year: 1.33B
YoY: -0.5%
Net Income from Continuing Operations
1.32B
Prev Year: 1.33B
YoY: -0.5%
Noncontrolling Interests
-553.25M
Prev Year: -471.83M
YoY: -17.3%
Net Income from Continuing and Discontinued Operation
770.95M
Prev Year: 858.98M
YoY: -10.2%
Normalized Income
746.94M
Prev Year: 670.53M
YoY: +11.4%
Interest Income
33.59M
Prev Year: 47.34M
YoY: -29.0%
Basic EPS
-
Prev Year: 1.92
Interest Expense
307.66M
Prev Year: 225.51M
YoY: +36.4%
Diluted EPS
-
Prev Year: 1.91
Net Interest Income
-274.07M
Prev Year: -178.17M
YoY: -53.8%
Weighted Average Shares (basic)
-
Prev Year: 448.19M
EBIT
1.63B
Prev Year: 1.56B
YoY: +4.9%
Weighted Average Shares (diluted)
-
Prev Year: 594.11M
EBITDA
1.64B
Prev Year: 1.56B
YoY: +5.1%
Reconciled Depreciation
3.85M
Prev Year: 0
Net Income from Continuing Operation Net Minority Interest
770.95M
Prev Year: 858.98M
YoY: -10.2%
Normalized EBITDA
1.61B
Prev Year: 1.37B
YoY: +17.8%
Total Unusual Items
24.01M
Prev Year: 188.46M
YoY: -87.3%
Total Unusual Items Excluding Goodwill
24.01M
Prev Year: 188.46M
YoY: -87.3%
Total Expenses
818.67M
Prev Year: 971.13M
YoY: -15.7%
Total Operating Income as Reported
1.56B
Prev Year: 1.29B
YoY: +20.7%
Diluted NI Available to Com Stockholders
1.01B
Prev Year: 1.14B
YoY: -11.5%
Average Dilution Earnings
234.57M
Prev Year: 276.89M
YoY: -15.3%
Values in USD

Royalty Pharma key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$2.4B$2.3B$2.4B$2.2B$2.3B
Operating income$1.6B$1.3B$1.5B$922.9M$1.4B
Net income$770.9M$859.0M$1.1B$42.8M$619.7M
Diluted EPS–$1.91$2.53$0.10$1.49
Total assets$19.6B$18.2B$16.4B$16.8B$17.5B
Total liabilities$9.9B$7.9B$6.3B$7.3B$7.3B
Shareholders' equity$6.5B$6.9B$6.5B$5.6B$5.8B
Cash and short-term investments$1.5B$1.8B$1.2B$2.4B$2.8B
Total debt$9.0B$7.6B$6.1B$7.1B$7.1B
Operating cash flow$2.5B$2.8B$3.0B$2.1B$2.0B
Free cash flow$2.5B$2.8B$3.0B$2.1B$2.0B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2017.

Questions and answers

What was Royalty Pharma's revenue in fiscal year 2025?

$2.38 billion, up 5.1% from $2.26 billion in fiscal year 2024.

How much profit does Royalty Pharma make?

Royalty Pharma reported net income of $770.95 million for fiscal year 2025 (32.4% of revenue); operating income was $1.56 billion.

How much cash and debt does Royalty Pharma have?

At the end of fiscal year 2025: cash and short-term investments of $1.49 billion and total debt of $8.95 billion.

What is Royalty Pharma's free cash flow?

$2.49 billion in fiscal year 2025 (operating cash flow of $2.49 billion).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube